BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 28, 2025
Home » Newsletters » BioWorld

BioWorld

Dec. 27, 2017

View Archived Issues

Bench Press: BioWorld looks at translational medicine

When they are directed against the wrong targets, immunoglobulin gamma (IgG) antibodies are the drivers of many autoimmune disorders. But high-dose IgG antibodies are also used to resolve inflammation. Read More

Regulatory front

The U.S. Government Accountability Office said in a Dec. 19 report that the estimated volume of pharmaceutical and biotechnology sales revenues rose from $534 billion in 2006 to $775 billion in 2015, and that roughly two-thirds of companies saw an increase in profit margins over the same term. GAO said the 25 largest firms had profit margins of between 15 and 2 percent, substantially greater than the 4 to 9 percent enjoyed by the 500 largest global companies in other industries. Read More

In the clinic

Glycotope GmbH, of Berlin, said it enrolled the first patient in its international GATTO study combining two of its immuno-oncology assets. Read More

Financings

Proteostasis Therapeutics Inc., of Cambridge, Mass., closed its public offering of 9.2 million shares of common stock, including 1.2 million shares issued to cover full overallotments, priced at $5 apiece. Read More

Other news to note

Antares Pharma Inc., of Ewing, N.J., said a written request for a type A meeting, along with a comprehensive briefing document, have been submitted to the FDA, in response to the complete response letter regarding the NDA for Xyosted, the company's drug for the treatment of testosterone deficiency (hypogonadism). Read More

Holiday notice

BioWorld's offices were closed in observance of Christmas. Read More

Perspectives on a challenging year: the biopharmaceutical industry has its say

In many ways it has been a challenging year for the biopharmaceutical industry and it is certain that company executives will be glad to close the curtains on a period that has made planning difficult. Read More

Learnings aside, hope for amyloid springs eternal

Given the state of Alzheimer's disease (AD) drug development, one might wonder whether those engaged in it also suffer from memory loss. Read More

La Jolla gifted early stocking stuffer with FDA shock drug approval

Two months ahead of its PDUFA date, La Jolla Pharmaceutical Co. has won FDA approval for a new vasopressor capable of increasing blood pressure in adults with septic or other distributive shock. Read More

Roche 'Ignyta' fire in M&A targeted therapy takeout

Roche Holding AG is acquiring San Diego-based Ignyta Inc. for $1.7 billion with an offer of $27 per share in cash, a 74 percent increase over its closing price on Thursday. Read More

Biggest newsmakers and trending stories of 2017

Despite a roiling political environment on both sides of the Atlantic and what Science called "epic estrangement" between the U.S. president and the scientific community, the biopharma industry produced dazzling clinical breakthroughs in 2017 while U.S. regulators logged record nods, including the first for gene therapy. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing